The duo from the Critical Path Institute detailed the thought process behind evaluating the importance of specific biomarkers and their relation to disability progression in Alzheimer disease.
Sudhir Sivakumaran, PhD
Advertisement
Articles by Sudhir Sivakumaran, PhD
The duo from the Critical Path Institute discussed how CPAD is revolutionizing data collection within the Alzheimer disease community and the advantages it brings to clinicians.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 2 OPAL Study to Test Muscle-Targeting Therapy Apitegromab in Infants With SMA
2
Interim ROSSINI Data Highlight Foslevodopa/Foscarbidopa’s Impact in Advanced Parkinson Disease
3
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related Amyloid Pathology
4
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
5
